Graeme-David Wald work email
- Valid
- Valid
Graeme-David Wald personal email
Experienced Director, Chairman and CEO with a demonstrated history of working in the capital markets industry and managing Life Science companies. Skilled in Financial Risk Management (Chairman of Audit & Risk Committee), Investment Funds and managing Life Science companies. Strong professional achievements demonstrated by restructuring and re-capitalising companies. Listed five companies on the ASX while at Wilson HTM and raised approximately $750M in primary and secondary offerings.I have worked with companies developing technologies that include analgesics, monoclonal antibodies, skin repair systems, cystic fibrosis, cardiac assist devices, sterilisation and disinfection and anaesthesia.
Myrio Therapeutics
-
Chief Executive OfficerMyrio Therapeutics Nov 2023 - PresentMelbourne, Victoria, AustraliaDeveloping bi-specific antibodies that can target peptide MHC on solid tumors.
-
DirectorSedarex Ltd Jun 2023 - PresentMelbourne, Victoria, Australia
-
Managing DirectorDrawbridge Pharmaceuticals Ltd Feb 2022 - Apr 2023Melbourne, Victoria, AustraliaDrawbridge is developing a novel general anaesthetic formulation with the potential to become a major player in the market as clinical trials have shown it to be safer than current general anaesthetics. It is also easier to manufacture. I led the corporate restructuring of the company and its recapitalisation. Put in place CMC and clinical strategies, and led negotiations with various service providers. Increased the company's market opportunity from US$1.6B p.a. to over US$3B p.a. Obtained in Principle Approval from the ASX to IPO the company.
-
Co-FounderCnj Ventures Dec 2019 - Jun 2022Melbourne, Victoria, AustraliaProvided advice to stock-broking companies and life-science companies about listing and secondary raises. Advised companies abut clinical trial structures, work required to bring products to market eg CMC and clinical requirements.
-
Founding Chairman And Acting CeoProta Therapeutics Pty Ltd Sep 2016 - Dec 2019Melbourne, Victoria, AustraliaLed investment by OneVentures into newly formed Prota Therapeutics, that licensed in technology from Murdoch Children's Hospital. I led the licensing negotiations and due-diligence for One Ventures that was the seed investor. As Chairman and Acting CEO when required, I built the clinical development and regulatory team to develop a novel immunotherapeutic drug treatment for food allergies. -
Investment Partner And PrincipalOne-Ventures Apr 2016 - Dec 2019Melbourne, Victoria, AustraliaFund manager specialising in life science companies. Played a major role in the developing the company's successful application to be a beneficiary of the Federal Governments Biomedical Translation Fund. Became a Principal in Healthcare Fund 3, where I sourced most of the Fund's investments. Led due diligence on investments, wrote investment reports, negotiated investment rounds and licensing agreements. Established the company's international Scientific Advisory Board. Led a team of portfolio managers and analysts.
-
Investment DirectorBioscience Managers Pty Ltd May 2012 - Mar 2016Melbourne, AustraliaInvestment Director at Bioscience Managers, an international fund manager specialising in the Life Science arena. -
DirectorGravitas Consulting & Investments Pty Ltd Feb 2012 - Feb 2016Melbourne, AustraliaA consulting company specialising investing in and advising life science companies on strategies, products, valuations, indications and regulatory pathways. Companies consulted to include those in the public and private sectors, with interests in respiratory diseases, analgesia and novel delivery systems.
-
DirectorNexvet Biopharma Oct 2013 - Jun 2015MelbourneNon-executive director of Nexvet, and chairman of the Risk and Audit Committee. Nexvet is developing a range of monoclonal antibodies (MAb's) for the veterinary market using proprietary technology (PETisation). This technology ensures the MAb is relevant for each respective animal species (dogs, cats and horses).
-
Head Of Life Sciences ResearchWilson Htm Oct 2003 - Jan 2012Running life since research, managing junior analysts and marketing of research reports. -
Vice President ResearchMerrill Lynch 1995 - 1999Research analyst
Graeme-David Wald Skills
Graeme-David Wald Education Details
-
Executive Course In Negotiations -
Chemistry -
Photoelectrochemistry -
Applied Chemistry
-
Chemistry And Applied Chemistry
Frequently Asked Questions about Graeme-David Wald
What company does Graeme-David Wald work for?
Graeme-David Wald works for Myrio Therapeutics
What is Graeme-David Wald's role at the current company?
Graeme-David Wald's current role is Myrio Therapeutics.
What is Graeme-David Wald's email address?
Graeme-David Wald's email address is gw****@****res.com
What schools did Graeme-David Wald attend?
Graeme-David Wald attended Harvard Business School, University Of The Witwatersrand, University Of The Witwatersrand, University Of Tennessee-Knoxville, Weizmann Institute Of Science, University Of The Witwatersrand, University Of The Witwatersrand.
What skills is Graeme-David Wald known for?
Graeme-David Wald has skills like Valuation, Investments, Lifesciences, Venture Capital, Business Strategy, Life Sciences, Management, Commercialization, Biotechnology, Start Ups, Business Development, Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial